{
    "references": [
        {
            "bibentry": "Zhang, J, Li, X, Han, X, et al. Targeting the thioredoxin system for cancer therapy. Trends Pharmacol Sci 2017; 38: 794–808. PMID: 28648527",
            "process_entry": "True",
            "doi": "10.1016/j.tips.2017.06.001",
            "pmid": "28648527",
            "xmlid": "CIT0001"
        },
        {
            "bibentry": "Stafford, WC, Peng, X, Olofsson, MH, et al. Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy. Sci Transl Med 2018; 10: eaaf7444. PMID: 29444979",
            "process_entry": "True",
            "doi": "10.1126/scitranslmed.aaf7444",
            "pmid": "29444979",
            "xmlid": "CIT0002"
        },
        {
            "bibentry": "Zhang, B, Zhang, J, Peng, S, et al. Thioredoxin reductase inhibitors: a patent review. Expert Opin Ther Pat 2017; 27: 547. PMID: 27977313",
            "process_entry": "True",
            "doi": "10.1080/13543776.2017.1272576",
            "pmid": "27977313",
            "xmlid": "CIT0003"
        },
        {
            "bibentry": "Laursen, JB, Nielsen, J. Phenazine natural products: biosynthesis, synthetic analogues, and biological activity. Chem Rev 2004; 104: 1663–86. PMID: 15008629",
            "process_entry": "True",
            "doi": "10.1021/cr020473j",
            "pmid": "15008629",
            "xmlid": "CIT0004"
        },
        {
            "bibentry": "Price-Whelan, A, Dietrich, LEP, Newman, DK. Rethinking 'secondary' metabolism: physiological roles for phenazine antibiotics. Nat Chem Biol 2006; 2: 71–8. PMID: 16421586",
            "process_entry": "True",
            "doi": "10.1038/nchembio764",
            "pmid": "16421586",
            "xmlid": "CIT0005"
        },
        {
            "bibentry": "Pierson, IIS, Pierson, AE. Metabolism and function of phenazines in bacteria: impacts on the behaviour of bacteria in the environment and biotechnological processes. Appl Microbiol Biotechnol 2010; 86: 1659. PMID: 20352425",
            "process_entry": "True",
            "doi": "10.1007/s00253-010-2509-3",
            "pmid": "20352425",
            "pmcid": "PMC2858273",
            "xmlid": "CIT0006"
        },
        {
            "bibentry": "Gamage, SA, Spicer, JA, Rewcastle, GW, et al. Structure − activity relationships for pyrido, imidazo, pyrazolo, pyrazino, and pyrrolophenazinecarboxamides as topoisomerase-targeted anticancer agents. J Med Chem 2002; 45: 740–3. PMID: 11806725",
            "process_entry": "True",
            "doi": "10.1021/jm010330+",
            "pmid": "11806725",
            "xmlid": "CIT0007"
        },
        {
            "bibentry": "Muller, M. Pyocyanin induces oxidative stress in human endothelial cells and modulates the glutathione redox cycle. Free Radic Biol Med 2002; 33: 1527–33. PMID: 12446210",
            "process_entry": "True",
            "doi": "10.1016/s0891-5849(02)01087-0",
            "pmid": "12446210",
            "xmlid": "CIT0008"
        },
        {
            "bibentry": "Cimmino, A, Evidente, A, Mathieu, V, et al. Phenazines and cancer. Nat Prod Rep 2012; 29: 487–501. PMID: 22337153",
            "process_entry": "True",
            "doi": "10.1039/c2np00079b",
            "pmid": "22337153",
            "xmlid": "CIT0009"
        },
        {
            "bibentry": "Guttenberger, N, Blankenfeldt, W, Breinbauer, R. Recent developments in the isolation, biological function, biosynthesis, and synthesis of phenazine natural products. Bioorg Med Chem 2017; 25: 6149–66. PMID: 28094222",
            "process_entry": "True",
            "doi": "10.1016/j.bmc.2017.01.002",
            "pmid": "28094222",
            "xmlid": "CIT0010"
        },
        {
            "bibentry": "Lu, Y, Yan, Y, Wang, L, et al. Design, facile synthesis and biological evaluations of novel pyrano[3,2-α]phenazine hybrid molecules as antitumor agents. Eur J Med Chem 2017; 127: 928–43. PMID: 27836197",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2016.10.068",
            "pmid": "27836197",
            "xmlid": "CIT0011"
        },
        {
            "bibentry": "Shen, Z, Chen, T, Ma, X, et al. Multifunctional theranostic nanoparticles based on exceedingly small magnetic iron oxide nanoparticles for T1-weighted magnetic resonance imaging and chemotherapy. ACS Nano 2017; 11: 10992–1004. PMID: 29039917",
            "process_entry": "True",
            "doi": "10.1021/acsnano.7b04924",
            "pmid": "29039917",
            "xmlid": "CIT0012"
        },
        {
            "bibentry": "Chen, C, Xie, X, Zhou, Q, et al. EGF-functionalized single-walled carbon nanotubes for targeting delivery of etoposide. Nanotechnology 2012; 23: 045104. PMID: 22222202",
            "process_entry": "True",
            "doi": "10.1088/0957-4484/23/4/045104",
            "pmid": "22222202",
            "xmlid": "CIT0013"
        },
        {
            "bibentry": "Wu, W, Li, R, Bian, X, et al. Covalently combining carbon nanotubes with anticancer agent: preparation and antitumor activity. ACS Nano 2009; 3: 2740–50. PMID: 19702292",
            "process_entry": "True",
            "doi": "10.1021/nn9005686",
            "pmid": "19702292",
            "xmlid": "CIT0014"
        },
        {
            "bibentry": "Wang, HW, Wei, YH, Guo, HW. Reduced nicotinamide adenine dinucleotide (NADH) fluorescence for the detection of cell death. Anticancer Agents Med Chem 2009; 9: 1012–7. PMID: 19663784",
            "process_entry": "True",
            "doi": "10.2174/187152009789377718",
            "pmid": "19663784",
            "xmlid": "CIT0015"
        },
        {
            "bibentry": "Yu, JS, Guo, HW, Wang, HW, et al. Increase of reduced nicotinamide adenine dinucleotide fluorescence lifetime precedes mitochondrial dysfunction in staurosporine-induced apoptosis of HeLa cells. J Biomed Optics 2011; 16: 036008.",
            "process_entry": "True",
            "xmlid": "CIT0016"
        },
        {
            "bibentry": "Lu, J, Holmgren, A. The thioredoxin antioxidant system. Free Radic Biol Med 2014; 66: 75–87. PMID: 23899494",
            "process_entry": "True",
            "doi": "10.1016/j.freeradbiomed.2013.07.036",
            "pmid": "23899494",
            "xmlid": "CIT0017"
        },
        {
            "bibentry": "Harris, IS, Treloar, AE, Inoue, S, et al. Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cells 2015; 27: 211–22.",
            "process_entry": "True",
            "xmlid": "CIT0018"
        },
        {
            "bibentry": "Mandal, PK, Schneider, M, Kolle, P, et al. Loss of thioredoxin reductase 1 renders tumors highly susceptible to pharmacologic glutathione deprivation. Cancer Res 2010; 70: 9505–14. PMID: 21045148",
            "process_entry": "True",
            "doi": "10.1158/0008-5472.can-10-1509",
            "pmid": "21045148",
            "xmlid": "CIT0019"
        },
        {
            "bibentry": "Chen, W, Tuladhar, A, Rolle, S, et al. Brevetoxin-2, is a unique inhibitor of the C-terminal redox center of mammalian thioredoxin reductase-1. Toxicol Appl Pharm 2017; 329: 58–66.",
            "process_entry": "True",
            "xmlid": "CIT0020"
        },
        {
            "bibentry": "Fang, J, Lu, J, Holmgren, A. Thioredoxin reductase is irreversibly modified by curcumin: a novel molecular mechanism for its anticancer activity. J Biol Chem 2005; 280: 25284–90. PMID: 15879598",
            "process_entry": "True",
            "doi": "10.1074/jbc.m414645200",
            "pmid": "15879598",
            "xmlid": "CIT0021"
        },
        {
            "bibentry": "Xie, LN, Luo, ZD, Zhao, ZN, Chen, TF. Anticancer and antiangiogenic iron (ii) complexes that target thioredoxin reductase to trigger cancer cell apoptosis. J Med Chem 2017; 60: 202–14. PMID: 28001402",
            "process_entry": "True",
            "doi": "10.1021/acs.jmedchem.6b00917",
            "pmid": "28001402",
            "xmlid": "CIT0022"
        },
        {
            "bibentry": "Chen, Q, Sandalova, T, Lindqvist, Y, Arnér, E. Crystal structure and catalysis of the selenoprotein thioredoxin reductase 1. J Biol Chem 2009; 284: 3998–4008. PMID: 19054767",
            "process_entry": "True",
            "doi": "10.1074/jbc.m807068200",
            "pmid": "19054767",
            "xmlid": "CIT0023"
        },
        {
            "bibentry": "Cox, AG, Brown, KK, Arner, ESJ, Hampton, MB. The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation. Biochem Pharm 2008; 76: 1097–109. PMID: 18789312",
            "process_entry": "True",
            "doi": "10.1016/j.bcp.2008.08.021",
            "pmid": "18789312",
            "xmlid": "CIT0024"
        },
        {
            "bibentry": "Hattori, K, Naguro, I, Runchel, C, Ichijo, H. The roles of ASK family proteins in stress responses and diseases. Cell Commun Signal 2009; 7: 9. PMID: 19389260",
            "process_entry": "True",
            "doi": "10.1186/1478-811X-7-9",
            "pmid": "19389260",
            "pmcid": "PMC2685135",
            "xmlid": "CIT0025"
        },
        {
            "bibentry": "Branco, V, Coppo, L, Solá, S, et al. Impaired cross-talk between the thioredoxin and glutathione systems is related to ASK-1 mediated apoptosis in neuronal cells exposed to mercury. Redox Biol 2017; 13: 278–87. PMID: 28600984",
            "process_entry": "True",
            "doi": "10.1016/j.redox.2017.05.024",
            "pmid": "28600984",
            "pmcid": "PMC5466585",
            "xmlid": "CIT0026"
        },
        {
            "bibentry": "Cuadrado, A, Nebreda, AR. Mechanisms and functions of p38 MAPK signalling. Biochem J 2010; 429: 403–17. PMID: 20626350",
            "process_entry": "True",
            "doi": "10.1042/bj20100323",
            "pmid": "20626350",
            "xmlid": "CIT0027"
        },
        {
            "bibentry": "Zeng, XS, Ji, JJ, Kwon, Y, et al. The role of thioredoxin-1 in suppression of endoplasmic reticulum stress in Parkinson disease. Free Radic Biol Med 2014; 67: 10–8. PMID: 24140863",
            "process_entry": "True",
            "doi": "10.1016/j.freeradbiomed.2013.10.013",
            "pmid": "24140863",
            "xmlid": "CIT0028"
        },
        {
            "bibentry": "Al-Gayyar, MMH, Abdelsaid, MA, Matragoon, S, et al. Thioredoxin interacting protein is a novel mediator of retinal inflammation and neurotoxicity. Br J Pharmacol 2011; 164: 170–80. PMID: 21434880",
            "process_entry": "True",
            "doi": "10.1111/j.1476-5381.2011.01336.x",
            "pmid": "21434880",
            "pmcid": "PMC3171869",
            "xmlid": "CIT0029"
        },
        {
            "bibentry": "Zhang, J, Zhang, B, Li, X, et al. Small molecule inhibitors of mammalian thioredoxin reductase as potential anticancer agents: an update. Med Res Rev 2019; 39: 5–39. PMID: 29727025",
            "process_entry": "True",
            "doi": "10.1002/med.21507",
            "pmid": "29727025",
            "xmlid": "CIT0030"
        },
        {
            "bibentry": "Fang, J, Holmgren, A. Inhibition of thioredoxin and thioredoxin reductase by 4-hydroxy-2-nonenal in vitro and in vivo. J Am Chem Soc 2006; 128: 1879–85. PMID: 16464088",
            "process_entry": "True",
            "doi": "10.1021/ja057358l",
            "pmid": "16464088",
            "xmlid": "CIT0031"
        },
        {
            "bibentry": "Chew, EH, Lu, J, Bradshaw, TD, Holmgren, A. Thioredoxin reductase inhibition by antitumor quinols: a quinol pharmacophore effct correlating to anti proliferative activity. FASEB J 2008; 22: 2072–83. PMID: 18180330",
            "process_entry": "True",
            "doi": "10.1096/fj.07-101477",
            "pmid": "18180330",
            "xmlid": "CIT0032"
        },
        {
            "bibentry": "Benstoem, C, Goetzenich, A, Kraemer, S, et al. Selenium and its supplementation in cardiovascular disease: what do we know? Nutrients 2015; 7: 3094–118. PMID: 25923656",
            "process_entry": "True",
            "doi": "10.3390/nu7053094",
            "pmid": "25923656",
            "pmcid": "PMC4446741",
            "xmlid": "CIT0033"
        }
    ],
    "localid": "MED-31179772",
    "doi": "10.1080/14756366.2019.1624541",
    "pmid": "10.1080/14756366.2019.1624541",
    "pmcid": "31179772",
    "curator": "BEE EuropeanPubMedCentralProcessor",
    "source_provider": "Europe PubMed Central",
    "source": "https://www.ebi.ac.uk/europepmc/webservices/rest/31179772/fullTextXML",
    "reference_pointers": [
        [
            {
                "n_rp": 0,
                "xref_id": "CIT0001",
                "rp_string": "1",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),205,325)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 1,
                "xref_id": "CIT0002",
                "rp_string": "2",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),675,161)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 2,
                "xref_id": "CIT0003",
                "rp_string": "3",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),675,161)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 3,
                "xref_id": "CIT0004",
                "rp_string": "4",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),1,157)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Phenazines, a large group of natural or synthetic nitrogen-containing heterocyclic compounds4,5, have been associated with anticancer activities since 19596. Previous work suggested that the anticancer modes of the existing analogues were reported as dual topoisomerase I/II7 and GSH depletion8, respectively. Besides those targets, the knowledge on modes of action and molecular targets of phenazine analogues are severely lagging behind9,10.",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 4,
                "xref_id": "CIT0005",
                "rp_string": "5",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),1,157)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Phenazines, a large group of natural or synthetic nitrogen-containing heterocyclic compounds4,5, have been associated with anticancer activities since 19596. Previous work suggested that the anticancer modes of the existing analogues were reported as dual topoisomerase I/II7 and GSH depletion8, respectively. Besides those targets, the knowledge on modes of action and molecular targets of phenazine analogues are severely lagging behind9,10.",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 5,
                "xref_id": "CIT0006",
                "rp_string": "6",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),1,157)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Phenazines, a large group of natural or synthetic nitrogen-containing heterocyclic compounds4,5, have been associated with anticancer activities since 19596. Previous work suggested that the anticancer modes of the existing analogues were reported as dual topoisomerase I/II7 and GSH depletion8, respectively. Besides those targets, the knowledge on modes of action and molecular targets of phenazine analogues are severely lagging behind9,10.",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            }
        ],
        [
            {
                "n_rp": 6,
                "xref_id": "CIT0007",
                "rp_string": "7",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),159,151)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Phenazines, a large group of natural or synthetic nitrogen-containing heterocyclic compounds4,5, have been associated with anticancer activities since 19596. Previous work suggested that the anticancer modes of the existing analogues were reported as dual topoisomerase I/II7 and GSH depletion8, respectively. Besides those targets, the knowledge on modes of action and molecular targets of phenazine analogues are severely lagging behind9,10.",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            },
            {
                "n_rp": 7,
                "xref_id": "CIT0008",
                "rp_string": "8",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),159,151)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "Phenazines, a large group of natural or synthetic nitrogen-containing heterocyclic compounds4,5, have been associated with anticancer activities since 19596. Previous work suggested that the anticancer modes of the existing analogues were reported as dual topoisomerase I/II7 and GSH depletion8, respectively. Besides those targets, the knowledge on modes of action and molecular targets of phenazine analogues are severely lagging behind9,10.",
                "pl_xpath": "/article/body/sec[1]/p[2]"
            }
        ],
        [
            {
                "n_rp": 8,
                "xref_id": "CIT0009",
                "rp_string": "9",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[6]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),311,133)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 9,
                "xref_id": "CIT0010",
                "rp_string": "10",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[7]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),311,133)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 10,
                "xref_id": "CIT0011",
                "rp_string": "11",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,392)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 11,
                "xref_id": "CIT0012",
                "rp_string": "12",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),683,235)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "In our previous study, a preliminary mechanism research indicated that a phenazine analogue (Figure 1(A)), namely CPUL1, which demonstrated antitumor activities against both mouse liver carcinoma cell lines (H22–H8D8) implanted xenografted mice in vivo and human liver carcinoma cell line (Hep G2) in vitro, might be acting as dual topoisomerase I and II inhibitors and apoptosis activator11. Intriguingly, with our ongoing study on the detailed antitumor molecular mechanism of compound CPUL1, we found that the compound was prevailingly distributed thoroughly in Hep G2 cell plasma not in cytoplast (Figure 1(B)), which was confirmed by laser scanning confocal microscopy (LSCM). This freakishly phenomenon was distinguishing from typical topoisomerase I/II inhibitors, such as doxorubicin12, etoposide13 and 10-hydroxycamptothecin14, which were reported as locating at nucleus in cancer cell lines by LSCM methods. The discrepant results of CPUL1 between the LSCM and topoisomerase I/II inhibition experiments aroused a suspicion that the CPUL1 might not targeting to the topoisomerase I/II in Hep G2 cell lines. Considering the controversial role of the CPUL1 against Hep G2 cells, the target of CPUL1 against Hep G2 cells becomes the crux of the scene to be unveiled. Thus, we attempted to discover and identify the anticancer target of CPUL1 in this study.",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            },
            {
                "n_rp": 12,
                "xref_id": "CIT0013",
                "rp_string": "13",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),683,235)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "In our previous study, a preliminary mechanism research indicated that a phenazine analogue (Figure 1(A)), namely CPUL1, which demonstrated antitumor activities against both mouse liver carcinoma cell lines (H22–H8D8) implanted xenografted mice in vivo and human liver carcinoma cell line (Hep G2) in vitro, might be acting as dual topoisomerase I and II inhibitors and apoptosis activator11. Intriguingly, with our ongoing study on the detailed antitumor molecular mechanism of compound CPUL1, we found that the compound was prevailingly distributed thoroughly in Hep G2 cell plasma not in cytoplast (Figure 1(B)), which was confirmed by laser scanning confocal microscopy (LSCM). This freakishly phenomenon was distinguishing from typical topoisomerase I/II inhibitors, such as doxorubicin12, etoposide13 and 10-hydroxycamptothecin14, which were reported as locating at nucleus in cancer cell lines by LSCM methods. The discrepant results of CPUL1 between the LSCM and topoisomerase I/II inhibition experiments aroused a suspicion that the CPUL1 might not targeting to the topoisomerase I/II in Hep G2 cell lines. Considering the controversial role of the CPUL1 against Hep G2 cells, the target of CPUL1 against Hep G2 cells becomes the crux of the scene to be unveiled. Thus, we attempted to discover and identify the anticancer target of CPUL1 in this study.",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            },
            {
                "n_rp": 13,
                "xref_id": "CIT0014",
                "rp_string": "14",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[6]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),683,235)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "In our previous study, a preliminary mechanism research indicated that a phenazine analogue (Figure 1(A)), namely CPUL1, which demonstrated antitumor activities against both mouse liver carcinoma cell lines (H22–H8D8) implanted xenografted mice in vivo and human liver carcinoma cell line (Hep G2) in vitro, might be acting as dual topoisomerase I and II inhibitors and apoptosis activator11. Intriguingly, with our ongoing study on the detailed antitumor molecular mechanism of compound CPUL1, we found that the compound was prevailingly distributed thoroughly in Hep G2 cell plasma not in cytoplast (Figure 1(B)), which was confirmed by laser scanning confocal microscopy (LSCM). This freakishly phenomenon was distinguishing from typical topoisomerase I/II inhibitors, such as doxorubicin12, etoposide13 and 10-hydroxycamptothecin14, which were reported as locating at nucleus in cancer cell lines by LSCM methods. The discrepant results of CPUL1 between the LSCM and topoisomerase I/II inhibition experiments aroused a suspicion that the CPUL1 might not targeting to the topoisomerase I/II in Hep G2 cell lines. Considering the controversial role of the CPUL1 against Hep G2 cells, the target of CPUL1 against Hep G2 cells becomes the crux of the scene to be unveiled. Thus, we attempted to discover and identify the anticancer target of CPUL1 in this study.",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            }
        ],
        [
            {
                "n_rp": 14,
                "xref_id": "CIT0015",
                "rp_string": "15",
                "rp_xpath": "/article/body/sec[3]/p[1]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[3]/p[1]),684,106)",
                "containers_title": [
                    "Results and discussion"
                ]
            }
        ],
        [
            {
                "n_rp": 15,
                "xref_id": "CIT0016",
                "rp_string": "16",
                "rp_xpath": "/article/body/sec[3]/p[1]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[3]/p[1]),684,106)",
                "containers_title": [
                    "Results and discussion"
                ]
            }
        ],
        [
            {
                "n_rp": 16,
                "xref_id": "CIT0017",
                "rp_string": "17",
                "rp_xpath": "/article/body/sec[3]/p[2]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[3]/p[2]),1,182)",
                "containers_title": [
                    "Results and discussion"
                ]
            }
        ],
        [
            {
                "n_rp": 17,
                "xref_id": "CIT0018",
                "rp_string": "18",
                "rp_xpath": "/article/body/sec[3]/p[2]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[3]/p[2]),1,182)",
                "containers_title": [
                    "Results and discussion"
                ]
            }
        ],
        [
            {
                "n_rp": 18,
                "xref_id": "CIT0018",
                "rp_string": "18",
                "rp_xpath": "/article/body/sec[3]/p[2]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[3]/p[2]),539,481)",
                "containers_title": [
                    "Results and discussion"
                ]
            }
        ],
        [
            {
                "n_rp": 19,
                "xref_id": "CIT0018",
                "rp_string": "18",
                "rp_xpath": "/article/body/sec[3]/p[4]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[3]/p[4]),1,170)",
                "containers_title": [
                    "Results and discussion"
                ]
            }
        ],
        [
            {
                "n_rp": 20,
                "xref_id": "CIT0020",
                "rp_string": "20–22",
                "pl_string": "20–22",
                "rp_xpath": "/article/body/sec[3]/p[4]/xref[2]",
                "pl_xpath": "/article/body/sec[3]/p[4]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[3]/p[4]),1,170)",
                "containers_title": [
                    "Results and discussion"
                ]
            },
            {
                "n_rp": 21,
                "xref_id": "",
                "pl_string": "20–22",
                "pl_xpath": "/article/body/sec[3]/p[4]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[3]/p[4]),1,170)",
                "containers_title": [
                    "Results and discussion"
                ]
            },
            {
                "n_rp": 22,
                "xref_id": "",
                "pl_string": "20–22",
                "pl_xpath": "/article/body/sec[3]/p[4]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[3]/p[4]),1,170)",
                "containers_title": [
                    "Results and discussion"
                ]
            }
        ],
        [
            {
                "n_rp": 23,
                "xref_id": "CIT0023",
                "rp_string": "23",
                "rp_xpath": "/article/body/sec[3]/p[4]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[3]/p[4]),477,231)",
                "containers_title": [
                    "Results and discussion"
                ]
            }
        ],
        [
            {
                "n_rp": 24,
                "xref_id": "CIT0024",
                "rp_string": "24",
                "rp_xpath": "/article/body/sec[3]/p[6]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[3]/p[6]),134,145)",
                "containers_title": [
                    "Results and discussion"
                ]
            }
        ],
        [
            {
                "n_rp": 25,
                "xref_id": "CIT0025",
                "rp_string": "25",
                "rp_xpath": "/article/body/sec[3]/p[8]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[3]/p[8]),1,319)",
                "containers_title": [
                    "Results and discussion"
                ]
            }
        ],
        [
            {
                "n_rp": 26,
                "xref_id": "CIT0026",
                "rp_string": "26",
                "rp_xpath": "/article/body/sec[3]/p[8]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[3]/p[8]),321,209)",
                "containers_title": [
                    "Results and discussion"
                ]
            }
        ],
        [
            {
                "n_rp": 27,
                "xref_id": "CIT0027",
                "rp_string": "27",
                "rp_xpath": "/article/body/sec[3]/p[10]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[3]/p[10]),1,232)",
                "containers_title": [
                    "Results and discussion"
                ]
            }
        ],
        [
            {
                "n_rp": 28,
                "xref_id": "CIT0028",
                "rp_string": "28",
                "rp_xpath": "/article/body/sec[3]/p[11]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[3]/p[11]),1,157)",
                "containers_title": [
                    "Results and discussion"
                ]
            }
        ],
        [
            {
                "n_rp": 29,
                "xref_id": "CIT0029",
                "rp_string": "29",
                "rp_xpath": "/article/body/sec[3]/p[11]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[3]/p[11]),159,217)",
                "containers_title": [
                    "Results and discussion"
                ]
            }
        ],
        [
            {
                "n_rp": 30,
                "xref_id": "CIT0026",
                "rp_string": "26",
                "rp_xpath": "/article/body/sec[3]/p[11]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[3]/p[11]),377,172)",
                "containers_title": [
                    "Results and discussion"
                ]
            }
        ],
        [
            {
                "n_rp": 31,
                "xref_id": "CIT0028",
                "rp_string": "28",
                "rp_xpath": "/article/body/sec[3]/p[11]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[3]/p[11]),377,172)",
                "containers_title": [
                    "Results and discussion"
                ]
            }
        ],
        [
            {
                "n_rp": 32,
                "xref_id": "CIT0030",
                "rp_string": "30",
                "rp_xpath": "/article/body/sec[3]/p[12]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[3]/p[12]),166,106)",
                "containers_title": [
                    "Results and discussion"
                ]
            }
        ],
        [
            {
                "n_rp": 33,
                "xref_id": "CIT0018",
                "rp_string": "18",
                "rp_xpath": "/article/body/sec[3]/p[12]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[3]/p[12]),273,113)",
                "containers_title": [
                    "Results and discussion"
                ]
            }
        ],
        [
            {
                "n_rp": 34,
                "xref_id": "CIT0021",
                "rp_string": "21",
                "rp_xpath": "/article/body/sec[3]/p[12]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[3]/p[12]),387,136)",
                "containers_title": [
                    "Results and discussion"
                ],
                "pl_string": "From above evidences, we preliminarily verified the CPUL1 could combine with TrxR1 and inhibit it at enzymes levels, cell levels and molecular levels, respectively. As far as we known, there are three main classes of TrxR1 inhibitors according to past research results30. The first class of TrxR1 inhibitors is binding to Sec-498 in TrxR1, such as Auranofin18 and iron(II) complexes22. The second type of TrxR inhibitors, for instance Curcumin21 and Brevetoxin 220, can attack both Sec-498 and Cys-58 active sites of TrxR. 4-hydroxy-2-nonenal31, quinols32 and Se compounds33, the third genre of TrxR inhibitors, could inhibit TrxR as well as Trx without selectivities.",
                "pl_xpath": "/article/body/sec[3]/p[12]"
            },
            {
                "n_rp": 35,
                "xref_id": "CIT0020",
                "rp_string": "20",
                "rp_xpath": "/article/body/sec[3]/p[12]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[3]/p[12]),387,136)",
                "containers_title": [
                    "Results and discussion"
                ],
                "pl_string": "From above evidences, we preliminarily verified the CPUL1 could combine with TrxR1 and inhibit it at enzymes levels, cell levels and molecular levels, respectively. As far as we known, there are three main classes of TrxR1 inhibitors according to past research results30. The first class of TrxR1 inhibitors is binding to Sec-498 in TrxR1, such as Auranofin18 and iron(II) complexes22. The second type of TrxR inhibitors, for instance Curcumin21 and Brevetoxin 220, can attack both Sec-498 and Cys-58 active sites of TrxR. 4-hydroxy-2-nonenal31, quinols32 and Se compounds33, the third genre of TrxR inhibitors, could inhibit TrxR as well as Trx without selectivities.",
                "pl_xpath": "/article/body/sec[3]/p[12]"
            }
        ],
        [
            {
                "n_rp": 36,
                "xref_id": "CIT0031",
                "rp_string": "31",
                "rp_xpath": "/article/body/sec[3]/p[12]/xref[6]",
                "context_xpath": "substring(string(/article/body/sec[3]/p[12]),524,145)",
                "containers_title": [
                    "Results and discussion"
                ],
                "pl_string": "From above evidences, we preliminarily verified the CPUL1 could combine with TrxR1 and inhibit it at enzymes levels, cell levels and molecular levels, respectively. As far as we known, there are three main classes of TrxR1 inhibitors according to past research results30. The first class of TrxR1 inhibitors is binding to Sec-498 in TrxR1, such as Auranofin18 and iron(II) complexes22. The second type of TrxR inhibitors, for instance Curcumin21 and Brevetoxin 220, can attack both Sec-498 and Cys-58 active sites of TrxR. 4-hydroxy-2-nonenal31, quinols32 and Se compounds33, the third genre of TrxR inhibitors, could inhibit TrxR as well as Trx without selectivities.",
                "pl_xpath": "/article/body/sec[3]/p[12]"
            },
            {
                "n_rp": 37,
                "xref_id": "CIT0032",
                "rp_string": "32",
                "rp_xpath": "/article/body/sec[3]/p[12]/xref[7]",
                "context_xpath": "substring(string(/article/body/sec[3]/p[12]),524,145)",
                "containers_title": [
                    "Results and discussion"
                ],
                "pl_string": "From above evidences, we preliminarily verified the CPUL1 could combine with TrxR1 and inhibit it at enzymes levels, cell levels and molecular levels, respectively. As far as we known, there are three main classes of TrxR1 inhibitors according to past research results30. The first class of TrxR1 inhibitors is binding to Sec-498 in TrxR1, such as Auranofin18 and iron(II) complexes22. The second type of TrxR inhibitors, for instance Curcumin21 and Brevetoxin 220, can attack both Sec-498 and Cys-58 active sites of TrxR. 4-hydroxy-2-nonenal31, quinols32 and Se compounds33, the third genre of TrxR inhibitors, could inhibit TrxR as well as Trx without selectivities.",
                "pl_xpath": "/article/body/sec[3]/p[12]"
            },
            {
                "n_rp": 38,
                "xref_id": "CIT0033",
                "rp_string": "33",
                "rp_xpath": "/article/body/sec[3]/p[12]/xref[8]",
                "context_xpath": "substring(string(/article/body/sec[3]/p[12]),524,145)",
                "containers_title": [
                    "Results and discussion"
                ],
                "pl_string": "From above evidences, we preliminarily verified the CPUL1 could combine with TrxR1 and inhibit it at enzymes levels, cell levels and molecular levels, respectively. As far as we known, there are three main classes of TrxR1 inhibitors according to past research results30. The first class of TrxR1 inhibitors is binding to Sec-498 in TrxR1, such as Auranofin18 and iron(II) complexes22. The second type of TrxR inhibitors, for instance Curcumin21 and Brevetoxin 220, can attack both Sec-498 and Cys-58 active sites of TrxR. 4-hydroxy-2-nonenal31, quinols32 and Se compounds33, the third genre of TrxR inhibitors, could inhibit TrxR as well as Trx without selectivities.",
                "pl_xpath": "/article/body/sec[3]/p[12]"
            }
        ]
    ]
}